Phase I Pharmacokinetic Study of Novel HIV-1 Capsid Inhibitor Lenacapavir Supports Potential for Every-6-Month SC Dosing

July 6-10, 2020; Virtual
Results demonstrate that this novel investigational first-in-class HIV-1 capsid inhibitor was generally well tolerated after single-dose administration in healthy volunteers, with PK supportive of a 6-month dosing interval.
Format: Microsoft PowerPoint (.ppt)
File Size: 228 KB
Released: July 10, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Produced in collaboration with
Educational grant provided by:
Gilead Sciences
ViiV Healthcare
Merck Sharp & Dohme Corp.

Related Content

Download CCO slides reviewing clinically relevant new data reported at CROI 2021 on a wide range of ART management topics.

Joseph J. Eron, Jr., MD Princy N. Kumar, MD, FIDSA, MACP Daniel R. Kuritzkes, MD Released: April 9, 2021

由专家选择的 2021 年 CROI 中的重要 HIV 数据,包括当前和研究性的 ART 疗法以及孕期和产后的 ART 疗法。数据由 CCO 提供

Princy N. Kumar, MD, FIDSA, MACP Daniel R. Kuritzkes, MD Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Released: April 9, 2021

Seleção por peritos de dados importantes sobre o VIH da CROI 2021, incluindo o ART atual e de investigação e o ART na gravidez e no período pós-parto, da CCO

Princy N. Kumar, MD, FIDSA, MACP Daniel R. Kuritzkes, MD Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Released: April 9, 2021

Selecciones de datos de CCO realizadas por expertos, con información destacada sobre el VIH procedente de CROI 2021, incluida sobre TAR actuales y en investigación y el uso de TAR durante el embarazo y el posparto.

Princy N. Kumar, MD, FIDSA, MACP Daniel R. Kuritzkes, MD Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Released: April 9, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue